Canada - English - Health Canada

sanis health inc - tamsulosin hydrochloride - tablet (extended-release) - 0.4mg - tamsulosin hydrochloride 0.4mg - selective alfa-1-adrenergic blocking agents

Canada - English - Health Canada

sivem pharmaceuticals ulc - tamsulosin hydrochloride - tablet (extended-release) - 0.4mg - tamsulosin hydrochloride 0.4mg - selective alfa-1-adrenergic blocking agents

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris limited - tamsulosin hydrochloride - modified-release capsule, hard - alpha-adrenoreceptor antagonists; tamsulosin

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - tamsulosin hydrochloride 0.4mg - capsule - 0.4 mg - active: tamsulosin hydrochloride 0.4mg excipient: brilliant blue fcf   carmoisine gelatin   talc (extragranular ingredients) ink iron oxide yellow magnesium stearate methacrylic acid - ethyl acrylate copolymer   microcrystalline cellulose ponceau 4r purified talc quinoline yellow sodium hydroxide sunset yellow fcf titanium dioxide     triacetin

Ireland - English - HPRA (Health Products Regulatory Authority)

synthon bv - tamsulosin hydrochloride - modified-release capsule, hard - 400 microgram(s) - alpha-adrenoreceptor antagonists; tamsulosin - alfa
1-adrenoceptor antagonist - lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph).

United States - English - NLM (National Library of Medicine)

directrx - tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - tamsulosin hydrochloride 0.4 mg - tamsulosin hydrochloride capsules, usp are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph) [see clinical studies (14)]. tamsulosin hydrochloride capsules, usp are not indicated for the treatment of hypertension. tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see adverse reactions (6.2)]. 8.1 pregnancy teratogenic effects, pregnancy category b. administration of tamsulosin hydrochloride to pregnant female rats at dose levels up to approximately 50 times the human therapeutic auc exposure (300 mg/kg/day) revealed no evidence of harm to the fetus. administration of tamsulosin hydrochloride to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. tamsulosin hydrochloride capsules are not indicated for use in wo

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - tamsulosin hydrochloride 0.4 mg - tamsulosin hydrochloride capsules usp are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph) [see clinical studies (14)]. tamsulosin hydrochloride capsules usp are not indicated for the treatment of hypertension. tamsulosin hydrochloride capsules usp are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules usp. reactions have included skin rash, urticaria, pruritus, angioedema and respiratory symptoms [see adverse reactions (6.2)]. teratogenic effects, pregnancy category b. administration of tamsulosin hydrochloride to pregnant female rats at dose levels up to approximately 50 times the human therapeutic auc exposure (300 mg/kg/day) revealed no evidence of harm to the fetus. administration of tamsulosin hydrochloride to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. tamsulosin hydrochloride capsules usp are not indicated for use in women. tamsulo

United States - English - NLM (National Library of Medicine)

carilion materials management - tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - tamsulosin hydrochloride 0.4 mg - tamsulosin hydrochloride capsules, usp are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph) [ ]. tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [ ]   administration of tamsulosin hydrochloride to pregnant female rats at dose levels up to approximately 50 times the human therapeutic auc exposure (300 mg/kg/day) revealed no evidence of harm to the fetus. administration of tamsulosin hydrochloride to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. tamsulosin hydrochloride capsules are not indicated for use in women. tamsulosin hydrochloride capsules are not indicated for use in women. tamsulosin hydrochloride capsules are not in

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - tamsulosin hydrochloride 0.4 mg - tamsulosin hydrochloride capsules, usp are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph) [see clinical studies (14)]. tamsulosin hydrochloride capsules, usp are not indicated for the treatment of hypertension. tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see adverse reactions (6.2)]. 8.1 pregnancy teratogenic effects, pregnancy category b. administration of tamsulosin hydrochloride to pregnant female rats at dose levels up to approximately 50 times the human therapeutic auc exposure (300 mg/kg/day) revealed no evidence of harm to the fetus. administration of tamsulosin hydrochloride to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. tamsulosin hydrochloride capsules are not indicated for use in women. 8.3

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - tamsulosin hydrochloride (unii: 11sv1951mr) (tamsulosin - unii:g3p28oml5i) - tamsulosin hydrochloride 0.4 mg - tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (bph) [see clinical studies (14)] . tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see adverse reactions (6.2)]. risk summary tamsulosin hydrochloride is not indicated for use in women. there are no adequate data on the developmental risk associated with the use of tamsulosin hydrochloride in pregnant women. no adverse developmental effects were observed in animal studies in which tamsulosin hydrochloride was administered to rats or rabbits during the period of organogenesis (gd 7 to 17 in the rat and gd 6 to 18 in the rabbit) [see data ]. in the u.s. general population